Novel small molecules and drug candidates targeting viral infections and metastatic cancers.
A NASAL SPRAY to figth Rhinitis (July 2024) : Project TITLE “Evaluation of the Therapeutic Effect of a Formulation Containing Mullein, Thyme, Propolis, and Long-Chain Polyphosphates in Children with Acute Rhinitis” The ELYAR (Elysium against rhinitis) Project: Clinical Trials.gov with the identifier : NCT06757179.
CONCLUSIONS: ” This study demonstrates the therapeutic efficacy of “Elysium Naso-gola,” an isotonic saline solution containing mullein, thyme, propolis, and long-chain polyphosphates, in the treatment of pediatric acute rhinitis in children. The primary endpoint showed a significant reduction in the severity of symptoms as measured by the I-NOSE questionnaire, with notable improvements observed after 5 days of treatment compared to the placebo group. Secondary outcomes, evaluated using the VAS scale, confirmed a significant reduction in nasal obstruction and a higher rate of complete resolution of acute rhinitis symptoms in the active treatment group. The data support the use of “Elysium Naso-gola” as an effective non-pharmacological treatment for acute rhinitis, highlighting its potential in reducing the severity and duration of symptoms. Moreover, the safety profile of the product was excellent, with no reported adverse events, underscoring its suitability for paediatric use.
A NASAL SPRAY to fight COVID19
Project title “A Clinical study: VIRALYSIUM” (20 February 2024-24 July 2024). Randomized double blind n.100 patients Covid infected ” UOC Malattie Infettive . AOU Federico II. Results are expected by the end of the year 2024. ELYSIUM Cell Bio ITA has developed a solution made by food additives (Polyphopshates – E452(i) Sodium polyphosphate) harmless to human body with antiviral properties. The mechanisms of action is based on: (i) human ACE2 receptor downregulation, (ii) viral RNA-dependend-RNA polymerase RdRp inibition, (iii) virus-host interaction displacement (by interaction with viral Spike protein).
Reference related to this issue:
https://pubmed.ncbi.nlm.nih.gov/34230209/
Italian Patent: n. 102023000016338, Aug 1 2023; n. 102024000005170, Mar 7 2024; EU patent application, European Patent EP24192124 31/07/2024 “Composition with antiviral, antibacterial and antifungal activity”
ANTI-VIRAL DRUGS PRODUCED:
N.2 Small molecules have been identified:
1- PI-7 An anti-PMCA1-ATP2B1 dealing with Ca++ homeostasis in cells infected by SARS-CoV-2.
Reference: https://www.medrxiv.org/content/10.1101/2022.09.02.22279542v1
2- Embo Reports
KoreanPatent: PDPB204106; PDPB204055
Article describing PI-7 findings:
2- ELYSIVIR against the PI3K/Akt and TGF beta signalling cascade during SARS-CoV-2 viral infection.
Italian Patent: n. 102023000022647; Oct 27 2023. All claims Accepted for Publication to the EPO bank.
NUTRACEUTICS
A small molecules is developed to fight metastatic cancer by takle tumour microenvironment , cellular T- and cellular metabolism and immune-systems. Pharmacokinetics and and Toxicology studies are undergoing. European Patent 28/10/2022 n. EP22204452, “Prune1 inhibitors Iand therapeutics use thereof ”.
Publications related to this issue: